QualityDipStocks / Health Care · Pharmaceuticals
SELLAS Life Sciences Group SLS
Outside our quality screen, so we don’t track its dips. It’s 45% below its 52-week high.
Outside our quality screen, 30% under its Market Value. No fair value estimate for now: there isn’t enough data.
- Fair value est.
- n/a
- Market Value
- $12.14price −30%
- Off 52-wk high
- −45%
- Risk vs market
- Highbeta 2.14
52-week range 51% of the way from its 52-week low to its high
Price $8.55Market Value $12.14
1 bullish · 4 bearish See why
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for SLS: Capital spending isn't tagged for the latest period in SEC XBRL data. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much SLS moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Swings much more than the market, and its own price swings are 8.5× the S&P 500’s.
- Beta vs S&P 500
- 2.14
- Volatility
- 109% vs 13% SPY
- Correlation SPY
- 0.25
- Correlation QQQ
- 0.26
Valuation details
MV $12.14
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 1 of 5
ValuationTrades 29.6% below its Market Value of $12.14, the average price paid since the Aug 11 filing.
Top bearish points 4 of 5
ProfitabilityOperating margin is only 0.0% over the last 12 months.
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%; no sales-growth data.
RiskSwings hard: beta 2.14 vs the S&P 500 and 109% yearly volatility (SPY 13%).
RiskReports earnings Nov 11: results can move the price sharply and reset Market Value.
All fundamentals
from SEC filings
No fundamentals for SELLAS Life Sciences Group: Latest SEC XBRL statements end 2026-06-30, too old to use. We show nothing rather than guess.
The business
- Gross margin0%
- Operating margin0%
- Return on equity−40%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $8.55
- 52-wk lowlowest close, 1 year$1.39−83.7%
- PriceMon Nov 2 close$8.55you are here
- Market Valueavg paid since Aug 11$12.14+42.0%
- 52-wk highhighest close, 1 year$15.46+80.8%
Momentum & 52-week range
RSI 34 · 5 days −24.6%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 11
- DateWed Nov 11
- Year-ago EPS($0.06)
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
SLS is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on SELLAS Life Sciences Group in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 5:14 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.